The Line on the Chart

The historical change is real. News of the NIH panel’s BMI 25 threshold appeared on 4 June 1998, and the formal federal release followed on 17 June. The archived NIH guideline defines overweight as BMI 25.0–29.9 and obesity as BMI 30 or above.² Contemporary federal practice had not used one universal 27.8 line: the National Center for Health Statistics used 27.8 for men and 27.3 for women, while other U.S. guidance used still other cutoffs. The change also aligned U.S. categories with international practice.

The roughly 29-million reclassification estimate is widely reported and plausible, but the official release emphasized that 97 million adults were overweight or obese in total, not a newly ill population. The panel described BMI as a risk-screening tool, added waist circumference, acknowledged muscular people could be misclassified, and based treatment on additional risk factors—not BMI alone. No one’s biology changed overnight; neither did the guideline claim it had.

The WHO working group did establish the familiar operational range: a bone-density T-score between −1 and −2.5. But it did not invent the word. Medical literature used osteopenia years earlier; a 1985 review, for example, described osteoporosis as a manifestation of osteopenia.⁴

The post is on firmer ground about breadth. The later WHO technical report says the category was expected to capture about half the population at some ages, and CDC data for 2017–2018 found low bone mass in 51.5% of U.S. women aged 50 and older.³⁵ Yet the same WHO report cautions that osteopenia should not be treated as a disease category; it was intended primarily for epidemiological description. Modern treatment decisions incorporate age, fracture history and absolute fracture probability. This is a genuine example of a descriptive category sometimes being over-medicalized in practice—but not proof that the category was invented to sell treatment.

A contemporaneous report described exactly that projection if the 2001 guideline were followed: an increase from approximately 13 million people taking cholesterol-lowering drugs to 36 million.⁷ ATP III expanded intensive treatment for higher-risk people while describing therapeutic lifestyle change as the foundation of primary prevention.⁶

The post’s “23 million new customers in one afternoon” is not a factual restatement. It converts a modeled implementation estimate into same-day prescribing, assumes every eligible person receives and continues medication, ignores lifestyle-first pathways, and substitutes commercial status for a clinical recommendation. The population estimate is real; the customer count is rhetoric.

JNC 7 introduced prehypertension for systolic pressure 120–139 or diastolic pressure 80–89, covering about 22% of adults—roughly 45 million people.²⁰ But the report explicitly stated that prehypertension was not a disease category and that people were not candidates for medication based on that blood pressure alone. The standard response was lifestyle modification.⁸

The designation was created because observational evidence showed cardiovascular risk rising continuously above lower blood pressures and because people in that range were more likely to develop hypertension. Whether “prehypertension” was a helpful warning or an unnecessarily medicalized label is debatable. Describing it as a drug-producing diagnosis contradicts the source document.

The population estimate is well supported. Applying the 2013 guideline to NHANES data increased adults aged 40–75 receiving or eligible for statins from 43.2 million to 56.0 million—a net 12.8 million. Of the increase, 10.4 million were in primary prevention and 8.3 million were over age 60.⁹ “None with heart disease” applies to the primary-prevention subgroup, not every person in the 12.8-million net increase.

The conflict-of-interest sentence mixes two episodes. A corrected BMJ record describes half of the 16-person 2013 panel as having current or recent industry ties; the guideline says relationships were disclosed and members were to recuse where relevant.¹⁰¹¹ The notorious finding that eight of nine authors had failed initially to disclose drug-company relationships concerned the 2004 NCEP update, not the 2013 guideline.¹² The 2004 episode is a serious, documented governance failure. Moving it nine years forward makes the viral post more dramatic but less accurate.

The guideline did define hypertension at 130/80 rather than 140/90, and national modeling estimated prevalence would rise from 31.9% to 45.6%—approximately 31.1 million additional adults.¹³¹⁴

The missing denominator is treatment. Only about 4.2 million additional adults were projected to be recommended antihypertensive medication; most newly classified adults were recommended nonpharmacological intervention alone. Diagnosis was also supposed to rest on averaged readings across multiple occasions, not one measurement. The label undeniably expanded. The implication that 31 million people became immediate pill customers did not.

These are the post’s strongest numbers because they closely reproduce a July 2026 JAMA analysis. Using 4,366 NHANES participants to represent 154.5 million adults aged 30–79 without known atherosclerotic cardiovascular disease, researchers estimated 87.5 million were statin eligible under the 2026 guideline, including 21.5 million newly eligible. The total was not 87.5 million prospective new users: 17.8% of the target population already reported taking statins, while another 8.6% met risk-independent criteria such as diabetes, chronic kidney disease or LDL cholesterol of at least 190 mg/dL. The newly eligible group’s mean estimated 10-year risk was 3.1%.¹⁶

Calling 3.1% “almost none” is not a neutral translation. If a risk model is calibrated, 3.1% means about three events per 100 similarly situated people over ten years—not zero. At the same time, it is a low short-term absolute risk, so expected absolute benefit is smaller and patient preference matters more. The 2026 guideline uses both 10-year and 30-year risk, describes lifestyle as foundational, and uses risk-enhancing factors and shared decisions rather than one universal automatic prescription rule.¹⁵

There is randomized-trial evidence of benefit even in lower-risk groups. A participant-level meta-analysis of 27 trials found about 11 fewer major vascular events per 1,000 people over five years for each 1 mmol/L LDL reduction among people with less than 10% five-year risk.¹⁷ That does not settle every individual decision; it shows why low absolute risk is not equivalent to no potential benefit.

In 2014, the panel appointed to JNC 8 recommended initiating medication at 150/90, rather than 140/90, for the general population aged 60 and older and set a treatment goal below 150/90.¹⁸ That recommendation was contested and later superseded, but it is exactly the kind of less aggressive threshold revision the post says never occurred.